CORR Insights®: What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis?

J. Jennings
{"title":"CORR Insights®: What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis?","authors":"J. Jennings","doi":"10.1097/CORR.0000000000000938","DOIUrl":null,"url":null,"abstract":"Osteomyelitis is a rare, but serious bone infection that may result from trauma, hematogenous spread, or chronic open wounds [12]. Treating osteomyelitis can be challenging because of antimicrobial resistance [9], biofilm formation [19], the presence of an avascular necrotic sequestrum [3], or internalization of bacteria within osteoblasts [25]. For elective surgical procedures like joint arthroplasty, antimicrobial therapy and aseptic techniques successfully prevent infection approximately 99% of the time [22], but once osteomyelitis has been established, the likelihood of treatment success varies widely, from 25% to 90% for established osteomyelitis, depending on many factors [6]. Early in the infectious process, antibiotic chemotherapy alone may eradicate osteomyelitis [5], though in moreadvanced or more severe infections, surgical débridement often comes into the picture [3], and surgical approaches may be augmented with targeted delivery of antibiotics directly to the affected tissue through local delivery devices such as antibiotic-loaded bone cement, calcium sulfate, or polymer sponges and gels [7, 10, 16, 24]. However, infection recurrence resulting from inadequate débridement or not clearing dormant biofilm bacteria can result in infection persistence, the need for repeat (andmore-aggressive) débridement, and even amputation of the affected limb [4, 8]. Novel therapeutics that both treat affected tissue and eradicate bacteria are desperately needed. The aim of the exploratory study by Muñoz and colleagues [13] is to determine whether a novel technique currently investigated for ablation of cancerous soft-tissue tumors might also have effective application in the treatment of osteomyelitis. The small preclinical study only followed animal outcomes for a 28-day period following treatment, but nonetheless provides promising evidence of a synergistic effect in killing Staphylococcus aureus within osteomyelitic bone.","PeriodicalId":10465,"journal":{"name":"Clinical Orthopaedics & Related Research","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Orthopaedics & Related Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CORR.0000000000000938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Osteomyelitis is a rare, but serious bone infection that may result from trauma, hematogenous spread, or chronic open wounds [12]. Treating osteomyelitis can be challenging because of antimicrobial resistance [9], biofilm formation [19], the presence of an avascular necrotic sequestrum [3], or internalization of bacteria within osteoblasts [25]. For elective surgical procedures like joint arthroplasty, antimicrobial therapy and aseptic techniques successfully prevent infection approximately 99% of the time [22], but once osteomyelitis has been established, the likelihood of treatment success varies widely, from 25% to 90% for established osteomyelitis, depending on many factors [6]. Early in the infectious process, antibiotic chemotherapy alone may eradicate osteomyelitis [5], though in moreadvanced or more severe infections, surgical débridement often comes into the picture [3], and surgical approaches may be augmented with targeted delivery of antibiotics directly to the affected tissue through local delivery devices such as antibiotic-loaded bone cement, calcium sulfate, or polymer sponges and gels [7, 10, 16, 24]. However, infection recurrence resulting from inadequate débridement or not clearing dormant biofilm bacteria can result in infection persistence, the need for repeat (andmore-aggressive) débridement, and even amputation of the affected limb [4, 8]. Novel therapeutics that both treat affected tissue and eradicate bacteria are desperately needed. The aim of the exploratory study by Muñoz and colleagues [13] is to determine whether a novel technique currently investigated for ablation of cancerous soft-tissue tumors might also have effective application in the treatment of osteomyelitis. The small preclinical study only followed animal outcomes for a 28-day period following treatment, but nonetheless provides promising evidence of a synergistic effect in killing Staphylococcus aureus within osteomyelitic bone.
CORR Insights®:不可逆电穿孔对兔骨髓炎金黄色葡萄球菌模型有何影响?
骨髓炎是一种罕见但严重的骨感染,可由创伤、血液传播或慢性开放性伤口引起[12]。由于抗菌素耐药性[9]、生物膜形成[19]、无血管坏死隔离体的存在[3]或成骨细胞内细菌的内化[25],治疗骨髓炎可能具有挑战性。对于选择性外科手术,如关节置换术,抗菌治疗和无菌技术成功预防感染的几率约为99%[22],但一旦确诊骨髓炎,治疗成功率差异很大,确诊骨髓炎的成功率从25%到90%不等,这取决于许多因素[6]。在感染过程的早期,单独使用抗生素化疗可以根除骨髓炎[5],但在更晚期或更严重的感染中,通常需要手术治疗[3],并且可以通过局部给药装置(如含抗生素的骨水泥、硫酸钙或聚合物海绵和凝胶)将抗生素直接靶向递送到受影响的组织,从而增加手术方法的作用[7,10,16,24]。然而,由于未充分清除或未清除休眠的生物膜细菌而导致的感染复发可导致感染持续存在,需要重复(且更具侵袭性)的感染,甚至截肢[4,8]。迫切需要既能治疗受感染组织又能根除细菌的新疗法。Muñoz等[13]探索性研究的目的是确定目前研究的一种用于软组织癌性肿瘤消融的新技术是否也可能有效应用于骨髓炎的治疗。这项小型临床前研究仅对治疗后28天的动物结果进行了跟踪,但仍然提供了有希望的证据,证明在杀死骨髓炎骨内的金黄色葡萄球菌方面具有协同作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信